Never an original thought in your life. LOL
P.S. You forgot the "multipier."
The Einstein of the Board. Thought SPPI diluted in the CASI deal. LOL
"cigan1956 cigan1956 • Oct 1, 2014 10:21 PM
Talk About The Share Dilution That Took Place Last Week Joe.
Come On Joe; Spew!"
P.S. SPPI does not "OWN CASI" either, SPPI merely acquired a 19.99% interest to get a "cash free" stake in China and CASI's potential blockbuster liver cancer drug.
P.S.S. Did you see the NEW Position for the: SPPI Director of Urology for Apaz too?
A pidly 6 to 8 multiple of the Revenues TODAY is $1.5 Billion. With CE and Apaz OR SPI-2012, SPPI is a $3 to $6 Billion market cap. A Biotech with $500 million to $1 Billion in current drug peak revenues ain't $1 to 2 B. WAY WAY More. Heck AVNR is 20 TImes is pidly never breakeven $100 million in revenues. Check out all of them. No biotech is even anywhere close as undervalued as SPPI.
Can Insiders purchase publicly-traded shares:
1. With knowledge of the release of an upcoming NDA;
2. Within 3 weeks or other applicable period prior to the Announcement of Quarterly Earnings or Annual Earnings;
3. With knowledge of SPI-2012 Phase II Primary and Secondary Endpoint Data which has not yet been Publicly Released?
What is your opinion as SPPI's legal advisor taking into account applicable SEC rules much less the still pending lawsuit and Fusilev investigation?
A. Yes, they sure can buy with reckless abandon; OR
B. No, they cannot under applicable SEC rules nor would it be prudent or advisable anyway from a legal standpoint.
Your call. P.S. The Answer is "B".
The NDA filing is not late. On August 7th at Q2 Earnings, the following was stated by Dr. Lee Allen:
"I was just going to add a little bit about -- a little more color on the FDA dialogue. Obviously, we don't usually talk about FDA communications. But this case, really, I mean, they were very encouraging. So although, again, it will be subject to a standard review, because that's what the 505(b)(2)s will get. We've already seen, our own case as an example, where sometimes decisions are made earlier than that. So we're very optimistic about the timeline for review. And we will be submitting that application in next several months."
Next several months could be anytime through November. Most likely in the next two weeks or so prior to November 7th and prior to 3rd Quarter Earnings release or shortly thereafter.
Wrong. Please educate yourself before speaking.
SPPI is a Delaware corporation and is governed by the Delaware Business Corporation Act. Krassner was VOTED ON the Board NOT voted off. A director does NOTneed to receive a majority of the shareholder vote if they are still one of the top vote getters for the proposed slate.
Whether Krassner should do the right thing and resign is another issue.
I get it and also agree with your analysis. I just like to "poke the panda bear". You also are right that shet is incapable of discussing any of the drugs, revenue stream, pipeline etc. Braindead.
Your paranoia and delusions are getting worse again:
1. No, of course not. Have not met Raj not anyone else at SPPI but intend to personally go to Henderson one day and thank Raj and his team for their contributions in the Fight to Beat Cancer. No compensation whatsoever. Ridiculous. Facts are facts and SPPI is stupidly undervalued; I don't need to be compensated by SPPI to figure that out.
2. Of course I own shares. Duh! How many is none of your business. It is safe to say, ALOT and ALOT. Clearly, SPPI by your own admission is the most undervalued Biotech on Planet Earth.
Even you have invested in SPPI for a few days in lieu of APPL and EXXON etc. 2x Revenues "don't take Einstein", much less with the upcoming Multiple Shots on Goal.
P.S. Go get help. You need it. "I don't do due diligence" is why you never finished at Fla and Gtown. Your paranoia and delusions are a;ps why you could not work with other partners. I am sure it was inspiring, engaging and motivating for others. A true Google work environment of creativity.
Current Assets are cash, equivalents, receivables, inventory. Here is NMM for last 3 years. Shortshet's favorite company that isn't simply a margined, triple leveraged index fund.
The SPPI forecasts are not "blue sky". CE Melphalan should dominate a $130 million market. Apaz's market is estimated at $200 to $300 million. The SPI-2012 market is, in fact, $6 Billion today. If it is found to be superior and a "BIOBETTER", it will necessarily Dominate the market. These are not mere predictions. Far from it. Ask the Tutes and Analysts.
Speaking of "pump dude" forecasts, rest assured YOU are MOST ASSUREDLY "forecasting" your TRIPLE MARGINED upro will go up given the Triple Leveraged nature product. Of course, this is all bogus hype too.
You also know the terms of the Debt. 2018 is the year to convert, raise money or pay off the debt. Many years to go. SPPI will pay off the debt by converting the debt to shares at a $25 PPS or higher share price. Effectively, there is ZERO debt and very minimal dilution. Like 3 or 4 million shares and that assumes they don't get S/H approval and use SPI-2012 to eliminate the debt.
Of course, it is basically all irrelevant since SPPI will likely be acquired before any of that occurs in 2018 anyway.
Off-label for mCRC is infringing on SPPI's orphan drug designation. The 150 and 200 sizes are off limits. Any use off-label or otherwise is strictly prohibited and SPPI will most assuredly seek the maximum supportable damages. Until 2019, Sandoz is in "timeout" even if they win the patent suit which they will NOT do so imho.
Meant CE Melphalan will add another $70 to $100 million annually fairly rapidly. Thus, Revenues should increase from $190 to $200 million UP to $270 to $300 Million run rate.
Will likely be raised in early 2015 after CE Melph filing at year-end and Q1 15 announcement of SPI-2012 data at the Medical Conference. If SPI-2012 data solidly confirms Bio-equivalent status much less Biobetter, what is a Market Cap Target for a company with $200 million in revenues getting ready to add $100 million on CE Melp and $600 million to a $1 B on SPI-2012 in a couple of years.
Discount $800 million to $1.2 Billion in Revenue Run Rate. It ain't a $1 B market cap....Maybe $3 to $5 BILLION
Does Fusilev not have Orphan Drug Status until 2018 anyway. If so, does SPPI not have 100% rights to Fusilev until sometime in 2018 regardless of whether the Patent is valid which it will be upheld imo anyway.
Thus, even if the generics won, aren't they "playing with themselves" anyway until mid-2018?
ZERO chance. There is a greater chance that the Isle of Man will acquire Great Britain. Any buyout of SPPI is off the table until SPPI has a minimum PPS of $25 to $30 ($2 billion market cap). Then, it will take a $40 PPS offer minimum.
stockstoshort • Feb 27, 2013 8:55 PM Flag
i am a daytrader who thoroughly studies a stock for at least 2-3 months before trading
i may never short-long sppi due to lack of daily trade range and low volumes
i rarely commit long term, short or long
currently i trade stocks that experience daily $1-$3 swings
observations on sppi - - -
with rare exceptions, sppi trades under 50 pennies daily swings, light volume
stuck in an annual range, going nowhere dramatically up or down
when listened to the recent cc playback, ceo sounded like salesman, not doctor
dont understand why posters here are so excited long term, just dont see it
0% chance of sellout, 99% chance of acquiring someone else to reduce income tax burden
may end up leaving this one alone and disappearing from your lives
would i be missed? :) Less